Experts reassess endpoints, patient selection, targets, and timing for the development of successful immune-based treatments ...

A compelling session at the EHA Congress explored how space research is reshaping our understanding of hematologic processes.

Positive updates across all programs, including longer term efficacy and safety data from the HELIOS open-label extension ...

Sessions and posters at the 2025 European Hematology Association Congress evaluated the potential and real-world practices of using artificial intelligence (AI) to predict and improve outcomes for ...

Adolescent and young adult (AYA) patients with hematological diseases have unique needs that require a multidisciplinary ...

CHICAGO — Counties in the U.S. with the highest environmental burden, such as increased pollution, had significantly higher ...

For patients with metastatic HR+/HER2— breast cancer, there were various trials to have come out of ASCO 2025 that are worth keeping your eye on.

CHICAGO — In this video, Erica L. Mayer, MD, MPH, discusses the SERENA-6 study, which assessed the efficacy of switching to camizestrant plus a CDK 4/6 inhibitor vs. continuing standard ...

Golidocitinib demonstrated promising efficacy in maintaining and enhancing tumor response in peripheral T-cell lymphoma (PTCL ...

The FDA granted fast track designation to nuvisertib for those with intermediate or high-risk myelofibrosis, which ...

Australian researchers have demonstrated that the use of a new, less toxic drug combination after stem cell transplants for ...

FDA Commissioner Martin Makary, MD, shared his vision for a “New FDA” with biopharma leaders attending BIO in Boston.